# Serum alkaline phosphatase levels at admission are associated with unfavorable prognosis in acute ischemic stroke patients undergoing endovascular thrombectomy

**Authors:** Xiaohong Tang, Qingyun Li, Wei Zhang

PMC · DOI: 10.3389/fneur.2026.1738653 · Frontiers in Neurology · 2026-02-17

## TL;DR

Higher serum alkaline phosphatase levels at admission are linked to worse outcomes in stroke patients treated with endovascular thrombectomy.

## Contribution

This study identifies serum ALP as a novel prognostic biomarker in acute ischemic stroke patients undergoing thrombectomy.

## Key findings

- Patients with unfavorable prognosis had significantly higher ALP levels compared to those with favorable outcomes.
- Each 10-unit increase in ALP was associated with a 17% higher odds of unfavorable prognosis after adjustment.
- The highest ALP tertile showed over three times higher odds of unfavorable prognosis compared to the lowest tertile.

## Abstract

Limited data exist on the association between alkaline phosphatase (ALP) levels and outcomes in acute ischemic stroke patients undergoing endovascular thrombectomy. This study aimed to evaluate the relationship between serum ALP levels at admission and unfavorable prognosis following endovascular thrombectomy.

This retrospective study included patients who underwent mechanical thrombectomy for acute ischemic stroke (AIS) within 24 h of symptom onset at the Affiliated Hospital of Xuzhou Medical University between October 2018 and May 2025. Blood samples were collected upon admission in the emergency room. Unfavorable prognosis was defined as a modified Rankin Scale score of 3–6 at 90 days. Logistic regression analyses were conducted to examine the relationship between ALP levels and unfavorable prognosis.

Of the 385 enrolled patients, 209 (54.3%) experienced an unfavorable prognosis. These patients exhibited significantly higher serum ALP levels (83.8 ± 29.5 U/L versus 76.1 ± 27.9 U/L; p = 0.009) compared to those with a favorable prognosis. A significant positive association was found between ALP levels (per 10-unit increase) and unfavorable prognosis (OR: 1.17, 95% CI: 1.06–1.29; p = 0.002) after adjusting for multiple variables. Patients in the highest ALP tertile had significantly higher odds of an unfavorable prognosis compared to those in the lowest tertile (OR: 3.17, 95% CI: 1.61–6.24; p = 0.001). The restricted cubic spline indicated a positive linear relationship between ALP levels and unfavorable prognosis (p for non-linearity = 0.461). The association between ALP levels and unfavorable prognosis remained stable across different subgroups (all p for interaction > 0.05).

Our findings demonstrate a positive association between serum ALP levels at admission and unfavorable prognosis in patients with AIS who underwent endovascular thrombectomy.

## Full-text entities

- **Genes:** SLC17A5 (solute carrier family 17 member 5) [NCBI Gene 26503] {aka AST, ISSD, NSD, SD, SIALIN, SIASD}, Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, GPT (glutamic--pyruvic transaminase) [NCBI Gene 2875] {aka AAT1, ALT, ALT1, GPT1, SGPT}, Il6 (interleukin 6) [NCBI Gene 16193] {aka Il-6}, alp (alopecia, recessive) [NCBI Gene 11691], ALPP (alkaline phosphatase, placental) [NCBI Gene 250] {aka ALP, PALP, PLAP, PLAP-1}, Crp (C-reactive protein, pentraxin-related) [NCBI Gene 12944], INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}
- **Diseases:** liver and renal damage (MESH:D056486), coronary artery disease (MESH:D003324), systemic (MESH:D015619), PAD (MESH:D058729), embolism (MESH:D004617), infarct (MESH:D007238), lacunar infarcts (MESH:D059409), ACA (MESH:D020243), sepsis (MESH:D018805), hypertension (MESH:D006973), occlusion (MESH:D001157), death (MESH:D003643), ICH (MESH:D002543), arterial calcification (MESH:D061205), reperfusion injury (MESH:D015427), stent thrombosis (MESH:D013927), bone (MESH:D001847), myocardial infarction (MESH:D009203), infections (MESH:D007239), coagulopathy (MESH:D001778), CVD (MESH:D002318), AF (MESH:D001281), Thrombolysis in Cerebral Infarction (MESH:D002544), Acute Stroke (MESH:D020521), pneumonia (MESH:D011014), intracranial hemorrhage (MESH:D020300), white matter hyperintensities (MESH:D056784), hemorrhagic (MESH:D006470), ischemia (MESH:D007511), stenosis (MESH:D003251), cerebral small vessel disease (MESH:D059345), acute (MESH:D000208), AIS (MESH:D000083242), dyslipidemia (MESH:D050171), NIHSS (MESH:C538175), liver disease (MESH:D008107), Inflammatory (MESH:D007249), hyperglycemia (MESH:D006943), BBB dysfunction (MESH:C536830), DM (MESH:D009223), neuroinflammation (MESH:D000090862), arteriosclerosis (MESH:D001161), diabetes mellitus (MESH:D003920), posterior circulation stroke (MESH:D020520), calcification (MESH:D002114), malignancy (MESH:D009369), LVO (MESH:C536223)
- **Chemicals:** lipopolysaccharide (MESH:D008070), ATP (MESH:D000255), ET (-), Org 10172 (MESH:C035838), phosphate (MESH:D010710), adenosine (MESH:D000241), agmatine (MESH:D000376)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12953080/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12953080/full.md

## References

44 references — full list in the complete paper: https://tomesphere.com/paper/PMC12953080/full.md

---
Source: https://tomesphere.com/paper/PMC12953080